RBC Capital Reiterates Outperform on Avid Bioservices, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Sean Dodge has reiterated an Outperform rating on Avid Bioservices (NASDAQ:CDMO) and maintained a $7 price target.

March 07, 2024 | 1:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital maintains an Outperform rating and a $7 price target on Avid Bioservices.
The reiteration of an Outperform rating and maintenance of a $7 price target by a reputable analyst like Sean Dodge from RBC Capital is likely to instill confidence among investors and could positively influence Avid Bioservices' stock price in the short term. Analyst ratings, especially from well-regarded financial institutions, can significantly impact investor sentiment and stock prices.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100